title: [Place of fibrates for the treatment of patients with atherogenic dyslipidemia].
abstract: The demography of dyslipidemia has changed towards a more complex atherogenic dyslipidemia involving increased levels of LDL cholesterol, in particular highly atherogenic small dense particles, hypertriglyceridemia and low HDL cholesterol, together with increased levels of markers of inflammation, thrombogenesis and endothelial dysfunction. Statins were shown to significantly lower cardiovascular morbidity and mortality, but treated patients are still left with a high residual risk, in particular for those with metabolic syndrome, type 2 diabetes, or low HDL cholesterol levels. Fibrates have been shown to reduce plasma triglycerides and increase HDL cholesterol, while improving inflammation, thrombogenesis and endothelial dysfunction. Clinical trials with fibrates have demonstrated their potential to reduce cardiovascular morbidity and mortality too, often through other mechanisms than those of statins. Combination trials of statins with fibrates have shown a more complete improvement of lipid profile and risk markers than each class separately. In contrast with gemfibrozil, fenofibrate does not interact significantly with the pharmacokinetics of statins, and its combination with statins has been shown to have a low risk of muscular side-effects or liver toxicity. The ACCORD outcome trial is exploring possible benefits of the combination of fenofibrate with statins on morbidity and mortality of patients with type 2 diabetes.
authors.affiliation: Service de Université Mons Hainaut, Belgique. jducobu@skynet.be
authors.forename: J
authors.initials: J
authors.lastname: Ducobu
authors.forename: A J
authors.initials: AJ
authors.lastname: Scheen
authors.forename: P
authors.initials: P
authors.lastname: Legat
authors.forename: G
authors.initials: G
authors.lastname: De Backer
authors.forename: L
authors.initials: L
authors.lastname: Van Gaal
authors.forename: B
authors.initials: B
authors.lastname: Velkeniers
authors.forename: J
authors.initials: J
authors.lastname: Kartounian
authors.forename: M
authors.initials: M
authors.lastname: Maes
authors.forename: M
authors.initials: M
authors.lastname: Hermans
mesh_terms: D050197:Atherosclerosis / Q000150:complications* / Q000628:therapy*; D002986:Clinical Trials as Topic; D002995:Clofibric Acid / Q000627:therapeutic use*; D050171:Dyslipidemias / Q000150:complications* / Q000628:therapy*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D002995:Clofibric Acid